0HQ1 Stock Overview Provides biological and chemical compound sample exploration and management solutions for the life sciences market in the United States, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Azenta Historical stock prices Current Share Price US$51.04 52 Week High US$69.06 52 Week Low US$39.24 Beta 1.5 1 Month Change 12.02% 3 Month Change 2.93% 1 Year Change -22.98% 3 Year Change -50.98% 5 Year Change 25.90% Change since IPO 74.39%
Recent News & Updates
Azenta, Inc., Annual General Meeting, Jan 30, 2025 Dec 18
Now 22% undervalued after recent price drop Dec 16
Azenta, Inc.(NasdaqGS:AZTA) dropped from S&P 400 Health Care (Sector) Nov 25
Independent Director recently bought US$495k worth of stock Nov 20
Full year 2024 earnings released: US$3.09 loss per share (vs US$0.19 loss in FY 2023) Nov 13 Azenta, Inc. Announces Chief Financial Officer Changes See more updates
Azenta, Inc., Annual General Meeting, Jan 30, 2025 Dec 18
Now 22% undervalued after recent price drop Dec 16
Azenta, Inc.(NasdaqGS:AZTA) dropped from S&P 400 Health Care (Sector) Nov 25
Independent Director recently bought US$495k worth of stock Nov 20
Full year 2024 earnings released: US$3.09 loss per share (vs US$0.19 loss in FY 2023) Nov 13 Azenta, Inc. Announces Chief Financial Officer Changes Azenta, Inc. to Report Q4, 2024 Results on Nov 12, 2024
Azenta, Inc Obtains Regulatory Approval for Clinical Long-Read Whole Genome Sequencing Test Nov 02 Azenta, Inc. Announces Management Changes
Forecast to breakeven in 2026 Aug 15
No longer forecast to breakeven Aug 07
New minor risk - Share price stability Aug 03
Azenta, Inc. to Report Q3, 2024 Results on Aug 06, 2024 Jul 25
Azenta, Inc. Provides Earnings Guidance for the Full Fiscal Year 2024 May 10
Second quarter 2024 earnings released: US$2.47 loss per share (vs US$0.029 loss in 2Q 2023) May 09 Stephen Schwartz to Retire as CEO of Azenta, Inc
Azenta, Inc. to Report Q2, 2024 Results on May 08, 2024 May 03
Now 21% overvalued May 01
High number of new directors Apr 26
Now 20% overvalued Apr 25
New major risk - Revenue and earnings growth Mar 15
First quarter 2024 earnings released: US$0.28 loss per share (vs US$0.15 loss in 1Q 2023) Feb 08
High number of new directors Feb 06 Azenta, Inc. Announces the Launch of the BioArc Ultra
Azenta, Inc. to Report Q1, 2024 Results on Feb 07, 2024 Jan 26
Azenta, Inc. Provides Earnings Guidance for the Fiscal Year 2024 Jan 19
Ellen M. Zane Decides Not to Stand for Election to the Board of Directors of Azenta, Inc Jan 18
Azenta, Inc., Annual General Meeting, Jan 30, 2024 Dec 16
Azenta, Inc. Provides Earnings Guidance for the Full Year Fiscal 2024 Nov 15
Full year 2023 earnings released: US$0.19 loss per share (vs US$0.15 loss in FY 2022) Nov 14
Azenta, Inc. to Report Q4, 2023 Results on Nov 13, 2023 Nov 09
Politan Capital Provides Information to the Shareholders Nov 02
Azenta, Inc. Announces Chief Financial Officer Changes, Effective October 16, 2023 Sep 28 Azenta, Inc. Announces Executive Vice President Changes, Effective October 16, 2023
Politan Capital Management Engages in Discussions with Azenta Sep 17
Politan Capital Management Engages in Discussions with Azenta Sep 16
New minor risk - Insider selling Aug 16
Insider recently sold US$407k worth of stock Aug 16
Third quarter 2023 earnings released: US$0.039 loss per share (vs US$0.094 loss in 3Q 2022) Aug 09 Azenta, Inc. Revises Revenue Guidance for the Full Year of 2023
Azenta, Inc. to Report Q3, 2023 Results on Aug 08, 2023 Aug 04
Forecast breakeven date pushed back to 2025 May 14
Second quarter 2023 earnings released: US$0.029 loss per share (vs US$0.024 loss in 2Q 2022) May 10
Azenta, Inc. Provides Earnings Guidance for the Third Quarter of Fiscal Year 2023 May 10
Azenta, Inc. to Report Q2, 2023 Results on May 09, 2023 May 04
First quarter 2023 earnings released: US$0.15 loss per share (vs US$0.038 profit in 1Q 2022) Feb 09
Azenta, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal Year 2023 Feb 09
Azenta, Inc. to Report Q1, 2023 Results on Feb 08, 2023 Feb 07
Azenta, Inc. (NasdaqGS:AZTA) acquired Ziath Ltd. Feb 04
Azenta, Inc. Announces Election of Directors Feb 03
Azenta, Inc., Annual General Meeting, Jan 31, 2023 Dec 22
Full year 2022 earnings released: US$0.15 loss per share (vs US$0.39 loss in FY 2021) Nov 16 Azenta Announces Board Resignations
Azenta, Inc. to Report Q4, 2022 Results on Nov 14, 2022 Nov 08
Azenta, Inc. Announces Matthew McManus Would No Longer Serve as the Companys Chief Operating Officer Effective as of October 14, 2022 Oct 18
Azenta, Inc. (NasdaqGS:AZTA) acquired B Medical Systems S.à R.L. from Navis Capital Partners. Oct 04
Executive VP & COO recently bought US$502k worth of stock Aug 23
Third quarter 2022 earnings released: US$0.094 loss per share (vs US$0.53 profit in 3Q 2021) Aug 11
Azenta, Inc. Provides Earnings Guidance for the Fourth Quarter Fiscal 2022 Aug 10
Azenta, Inc. (NasdaqGS:AZTA) entered into an agreement to acquire B Medical Systems S.à R.L. for approximately €460 million. Aug 09
Azenta, Inc. Provides Earnings Guidance for the Third Fiscal Quarter Ended June 30, 2022 Jul 14
Azenta, Inc.(NasdaqGS:AZTA) dropped from Russell 3000E Growth Index Jun 26
Azenta, Inc. announced delayed 10-Q filing May 12
Second quarter 2022 earnings released: US$0.024 loss per share (vs US$0.32 profit in 2Q 2021) May 11 Azenta, Inc. Provides Revenue Guidance for the Third Quarter of 2022 May 10
Azenta, Inc. to Report Q2, 2022 Results on May 03, 2022 Apr 15
Forecast breakeven date moved forward to 2022 Feb 12
Azenta, Inc. Provides Earnings Guidance for the Second Quarter Fiscal Year 2022 Feb 09
Azenta, Inc. Announces Executive Changes Feb 02
Forecast breakeven date pushed back to 2023 Dec 03 Azenta, Inc.(NasdaqGS:AZTA) dropped from NASDAQ Composite Index
Upcoming dividend of US$0.10 per share Nov 25
Independent Director recently sold US$323k worth of stock Nov 16
Full year 2021 earnings released: US$0.39 loss per share (vs US$0.88 profit in FY 2020) Nov 11
Insufficient new directors Nov 01
Insufficient new directors Oct 02
Insufficient new directors Oct 02
Brooks Automation, Inc. Introduces Azenta Life Sciences to Advance Innovative Sample Solutions Sep 30
Upcoming dividend of US$0.10 per share Aug 26
Brooks Automation, Inc. Provides Earnings Guidance for the Fourth Quarter of Fiscal 2021 Aug 08
Third quarter 2021 earnings released: EPS US$0.53 (vs US$0.19 in 3Q 2020) Aug 06
Brooks Automation, Inc.(NasdaqGS:BRKS) dropped from Russell 2000 Dynamic Index Jun 28 Shareholder Returns 0HQ1 GB Life Sciences GB Market 7D 2.6% -4.8% -0.6% 1Y -23.0% -30.0% 2.7%
See full shareholder returns
Return vs Market: 0HQ1 underperformed the UK Market which returned 2.7% over the past year.
Price Volatility Is 0HQ1's price volatile compared to industry and market? 0HQ1 volatility 0HQ1 Average Weekly Movement 7.6% Life Sciences Industry Average Movement 7.6% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.5% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: 0HQ1's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0HQ1's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in the United States, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates through three reportable segments: Sample Management Solutions, Multiomics, and B Medical Systems. The Sample Management Solutions segment provides sample management products and solutions, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services.
Show more Azenta, Inc. Fundamentals Summary How do Azenta's earnings and revenue compare to its market cap? 0HQ1 fundamental statistics Market cap US$2.29b Earnings (TTM ) -US$164.17m Revenue (TTM ) US$656.32m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0HQ1 income statement (TTM ) Revenue US$656.32m Cost of Revenue US$389.00m Gross Profit US$267.32m Other Expenses US$431.49m Earnings -US$164.17m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -3.60 Gross Margin 40.73% Net Profit Margin -25.01% Debt/Equity Ratio 0%
How did 0HQ1 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/26 22:12 End of Day Share Price 2024/12/26 00:00 Earnings 2024/09/30 Annual Earnings 2024/09/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Azenta, Inc. is covered by 18 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Christopher Muse Barclays Brett Hodess BofA Global Research Yuan Zhi B. Riley Securities, Inc.
Show 15 more analysts 